|

rezatapopt Clinical Trials

3 actively recruiting trials across 3 locations

No change since July 2026

Also known as: PC14586

Pipeline

Phase 1: 2Phase 1/2: 1

Top Sponsors

  • PMV Pharmaceuticals, Inc2
  • M.D. Anderson Cancer Center1

Indications

  • Cancer3
  • TP53 Y220C Mutation1
  • ER/PR(+), Her2(-) Breast Cancer1
  • ER/PR Positive Breast Cancer1
  • TNBC1

Irvine, California1 trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of California Irvine Chao Family Comprehensive Cancer Center

Phase 1/2

Denver, Colorado1 trial

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

HealthOne Denver

Phase 1

Tampa, Florida1 trial

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Moffitt Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.